Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 59

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Rheumatoid arthritis+1

Not yet recruiting

Testing the Safety of Combining Tocilizumab with Other Biologic Drugs in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Cardiff University

Systemic lupus erythematosus

Not yet recruiting

Comparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Study of Tenofovir Alafenamide as Add-on Treatment to Anti-CD20 Therapy in Multiple Sclerosis Patients to Reduce Neuronal Damage

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenofovir Alafenamide
  • Sponsor:Oslo University Hospital HF

Dermatitis atopic

Not yet recruiting

Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:University Of Michigan

Myasthenia gravis

Not yet recruiting

Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glucose

Systemic scleroderma+2

Not yet recruiting

Study of B Cell Response to Tetanus Toxoid Vaccination in Patients with Systemic Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TETANUS TOXOID
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Asthma

Not yet recruiting

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Salmeterol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not yet recruiting

Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
  • Sponsor:Aclaris Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not yet recruiting

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
  • Sponsor:Universitaetsklinikum Erlangen AöR

Axial spondyloarthritis+3

Not yet recruiting

Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.